Article
Genetic variations linked to increased PCa risk identified
The findings could help clinicians differentiate between slow-growing and aggressive tumors
Findings from a large international study have identified 22 genetic variations that are associated with an increased risk of developing prostate cancer.
READ: FDA approves label update for advanced PCa treatment
The study, which was published in Cancer Discovery (2015; 5:358-79), was conducted by the PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) consortium, whose goal is to identify genetic risk factors associated with prostate cancer.
Men who have a family history of prostate cancer have a two-fold greater risk of developing the disease. Currently, approximately 100 genetic variants have been found to influence the risk of prostate cancer. However, these variants only account for 33% of increased familial risk, suggesting that additional genetic factors must also exist, according to a press release from Moffitt Cancer Center in Tampa, FL, which participated in the study.
The researchers compared the genetic information from 22,301 prostate cancer cases and 22,320 normal control cases from 23 different clinical studies. The research team focused their analysis on microRNAs.
The authors discovered 22 microRNA binding site variations that influence the risk of developing prostate cancer. Among these 22 variations, 10 of them were not investigated thoroughly as being potential risk factors. Seven of the variants could differentiate between aggressive and nonaggressive disease.
NEXT: One variant plays role in mediating expression of PSA
More from Urology Times
Androgen receptor inhibitor shows significant PFS increase
Sexual effects data lacking on 5-ARI for hair loss
Study: Low-dose-rate BT outperforms EBRT boost
The authors further confirmed the importance of two of these genetic variants by investigating how they influence protein expression in normal and cancerous prostate tissue. They discovered that one of the variants plays an important role in mediating expression of PSA, and the second variant controls expression of a gene involved in metabolism.
ALSO SEE: Significant OS improvement seen with mCRPC Tx vs. placebo
“The hope is that this research may eventually lead to a simple genotyping based blood test that could be used in conjunction with the PSA and DRE tests to aid the medical team and patient in accurately predicting disease risk,” said co-author Jong Park, PhD, of Moffitt Cancer Center.
The results from this study may also allow physicians to differentiate between slow-growing and aggressive prostate tumors and aid in therapeutic decisions.
You might also like:
European data on PCa assay comparable to U.S. findings
Study uncovers 400% cost difference in BPH treatments
Workplace exertion among factors linked to male infertility
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.
